Biotechne Corp (TECH)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

614 MCKINLEY PL N E MINNEAPOLIS, MN 55413

Techne and subsidiaries are engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. Co. has two segments: biotechnology and hematology. Co.'s biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products. Co., through its biotechnology segment, supplies proteins such as cytokines and related reagents. Co. also produces and markets enzymes and intracellular signaling reagents. Co. also markets one type of immunoassay kit under the trade name Quantikine. Co.'s hematology segment develops and manufactures hematology controls and calibrators for both impedance and laser type cell counters.

Data as of 2020-10-17
Market Cap10.243 Billion Shares Outstanding38.556 Million Avg 30-day Volume172.397 Thousand
P/E Ratio45.8 Dividend Yield0.482 EPS5.8
Price/Sales18.442 Price cash flow ratio51.0 Price free cash flow ratio115.5
Book Value35.82 Price to Tangible Book75.1 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.308536
BETA0.975383 52-week High/Low286.68 / 155.17 Stddev0.075414

Are you looking for this stock instead?

View SEC Filings from TECH instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 6 5 20.0% 2 (0.13%) 0 (0.0%)
Funds Holding: 380 357 6.44% 77 (5.02%) 82 (5.24%) -6.1%
13F shares: 36.115 Million 36.415 Million -0.83% 9.124 Million 10.574 Million -13.72%
% Ownership 94.4844 94.9513 -0.49% 23.8694 27.5715 -13.43%
New Positions: 68 41 65.85% 12 18 -33.33%
Increased Positions 129 131 -1.53% 30 24 25.0%
Closed Positions 39 48 -18.75% 14 10 40.0%
Reduced Positions 135 117 15.38% 32 34 -5.88%
Total Calls 103.602 Thousand 41.4 Thousand 150.25% 20.6 Thousand 2 Thousand 930.0%
Total Puts 40.705 Thousand 86.8 Thousand -53.1% 22.4 Thousand
PUT/CALL Ratio 0.39 2.1 -81.43% 1.09 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding TECH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TECH BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KUMMETH CHARLES R. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
161,687 2020-08-09 10

HIPPEL JAMES CHIEF FINANCIAL OFFICER

  • Officer
9,137 2020-08-09 4

EANSOR NORMAN DAVID PRESIDENT-PROTEIN SCIENCES

  • Officer
1,318 2020-08-09 5

FURLOW BRENDA S. SVP - GENERAL COUNSEL

  • Officer
5,186 2020-08-09 5

KELDERMAN KIM PRES. DIAGNOSTICS & GENOM

  • Officer
1,668 2020-08-05 2

BUSHMAN JULIE L

0 2020-08-03 2

WIENS HAROLD J

4,843 2020-05-22 5

BAUMGARTNER ROBERT V

  • Director
9,221 2020-05-21 2

HIGGINS JOHN L

  • Director
4,021 2020-02-12 2

NUSSE ROELAND

  • Director
12,374 2019-11-25 2

STEER RANDOLPH C

  • Director
4,721 2019-10-24 1

SETH ALPNA

  • Director
1,748 2019-10-24 1

KEEGAN JOSEPH D

  • Director
1,748 2019-10-24 1

VESSEY RUPERT

  • Director
642 2019-10-24 1

DINARELLO CHARLES A

8,212 2018-08-08 0

BAZAN J. FERNANDO CHIEF TECHNICAL OFFICER

0 2017-10-26 0

GAVIN ROBERT M. SEN. VP PROTEIN PLATFORMS

1,667 2017-10-26 0

GOULD KEVIN S SVP CLINICAL CONTROLS

1,355 2017-10-26 0

LUCAS ROGER C

1,870 2017-10-10 0

HOLBROOK KAREN A

914 2017-09-06 0

VERONNEAU MARCEL SVP - CLINICAL CONTROLS

  • Officer
41,740 2015-08-07 0

OCONNELL HOWARD V

  • Director
72,000 2015-02-19 0

REAGAN KEVIN J SENIOR VP - BIOTECH

  • Officer
0 2014-12-05 0

MELSEN GREGORY J CFO

  • Officer
2,163 2013-08-01 0

OLAND THOMAS E CEO, PRESIDENT

  • Officer
  • Director
1,543,840 2011-11-30 0

HERBERT G A

  • Director
164,360 2008-10-23 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments